Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.
EXCLUSIVE: Understanding Real Estate For Psychedelic Treatments Boosted By Geospatial Mapping
Facing high patient demand for psychedelic-assisted therapies (PAT) once FDA-approved, two partner organizations are advancing an AI-powered solution to identify oversaturated clinic clusters and opportunities forward.
Psyched: Steve Cohen’s New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) has completed its Phase 1 study evaluating proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants.
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment
Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management firm, again showing support for the biopharma sector.
GH Research’s Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold
After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary inhalable 5-MeO-DMT compound GH001 on clinical hold due to “insufficient information to assess risks on huma
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.
EXCLUSIVE: Cannabis Catalysts Praise SAFER Momentum, Plus State Market Prospects
The cannabis industry is poised for some serious growth owing to the historic clearance of the SAFER Banking Act by the
PharmaTher Is ‘One Step Closer To Being A Ketamine Leader’ Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.